Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 AUD | +7.14% | -14.29% | +20.00% |
May. 23 | Firebrick Pharma Obtains Nasodine Composition Patent in South Africa | MT |
May. 17 | Firebrick Pharma Raises AU$800,000 via Placement | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Nasodine
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -79.87% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -79.87% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Goodall
FOU | Founder | - | 12-04-11 |
Chief Executive Officer | 70 | 12-04-11 | |
Kavi Bekarma
DFI | Director of Finance/CFO | - | 23-01-24 |
Simon Tucker
CTO | Chief Tech/Sci/R&D Officer | - | - |
Peter Friedland
CTO | Chief Tech/Sci/R&D Officer | - | - |
Monique Baldwin
LAW | General Counsel | - | - |
Robyn Branigan
SAM | Sales & Marketing | - | - |
Stephen Buckley
SEC | Corporate Secretary | - | 20-12-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Gardner
BRD | Director/Board Member | 73 | 20-11-12 |
Richard Treagus
BRD | Director/Board Member | 58 | 22-05-31 |
Chief Executive Officer | 70 | 12-04-11 | |
Stephen Goodall
FOU | Founder | - | 12-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 178,046,736 | 88,962,313 ( 49.97 %) | 0 | 49.97 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+20.00% | 7.78M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- FRE Stock
- Company Firebrick Pharma Limited